百花医药: 新疆百花村医药集团股份有限公司2021年股票期权激励计划行权结果暨股份变动公告

Core Viewpoint - The announcement details the stock option exercise plan of Xinjiang Baihua Village Pharmaceutical Group Co., Ltd., highlighting the completion of the third exercise period and the second reserved grant period, with a total of 253,760 shares exercised, representing 10.02% of the total exercisable stock options [2][10]. Summary by Sections Stock Option Exercise Details - From July 1, 2025, to July 31, 2025, a total of 253,760 shares were exercised, with cumulative exercises reaching 2,459,205 shares, accounting for 97.08% of the total exercisable stock options [2][10]. - The stock options will be listed for trading on the second trading day after the exercise date [2]. Decision-Making Process and Disclosure - The decision-making process involved several proposals regarding the stock option incentive plan, which were approved by the board and independent directors [3][4]. - The supervisory board did not receive any objections during the public notice period regarding the incentive plan [3]. Stock Option Cancellation - A total of 1,207,650 stock options were canceled due to non-fulfillment of exercise conditions, reducing the number of incentive recipients from 162 to 149 [5]. - The total number of unexercised stock options was adjusted from 12,100,000 to 10,892,350 after the cancellation [5]. Exercise Conditions and Results - The first exercise period conditions were deemed fulfilled, allowing 176 individuals to exercise a total of 3,937,175 stock options at a price of 4.98 yuan per share [6]. - The third exercise period and the second reserved grant period conditions were also confirmed as fulfilled, allowing 149 individuals to exercise a total of 2,533,245 stock options at the same price [7][8]. Financial Impact and Fundraising - The company raised 1,263,724.80 yuan from the exercise of 253,760 shares, with total funds raised from the stock option plan amounting to 46,878,134.40 yuan, used to supplement working capital [10]. - The total number of shares increased from 384,293,875 to 384,547,635, but this change did not significantly impact the company's financial status or operating results [10].